

# Timothy R Sterling

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4704523/publications.pdf>

Version: 2024-02-01

119  
papers

5,810  
citations

136950

32  
h-index

82547

72  
g-index

121  
all docs

121  
docs citations

121  
times ranked

6851  
citing authors

#	ARTICLE	IF	CITATIONS
1	Three Months of Rifapentine and Isoniazid for Latent Tuberculosis Infection. <i>New England Journal of Medicine</i> , 2011, 365, 2155-2166.	27.0	769
2	Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. <i>Clinical Infectious Diseases</i> , 2017, 64, e1-e33.	5.8	501
3	Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. <i>Clinical Infectious Diseases</i> , 2017, 64, 111-115.	5.8	492
4	Management of latent <i>Mycobacterium tuberculosis</i> infection: WHO guidelines for low tuberculosis burden countries. <i>European Respiratory Journal</i> , 2015, 46, 1563-1576.	6.7	475
5	Rising Obesity Prevalence and Weight Gain Among Adults Starting Antiretroviral Therapy in the United States and Canada. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 50-58.	1.1	231
6	Greater Weight Gain in Treatment-naïve Persons Starting Dolutegravir-based Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2020, 70, 1267-1274.	5.8	218
7	Latent TB Infection Treatment Acceptance and Completion in the United States and Canada. <i>Chest</i> , 2010, 137, 401-409.	0.8	197
8	Treatment for Preventing Tuberculosis in Children and Adolescents. <i>JAMA Pediatrics</i> , 2015, 169, 247.	6.2	187
9	Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada. <i>Journal of the International AIDS Society</i> , 2020, 23, e25484.	3.0	148
10	Impact of Risk Factors for Specific Causes of Death in the First and Subsequent Years of Antiretroviral Therapy Among HIV-Infected Patients. <i>Clinical Infectious Diseases</i> , 2014, 59, 287-297.	5.8	136
11	HIV Infection-Related Tuberculosis: Clinical Manifestations and Treatment. <i>Clinical Infectious Diseases</i> , 2010, 50, S223-S230.	5.8	120
12	Incidence of AIDS-Defining Opportunistic Infections in a Multicohort Analysis of HIV-infected Persons in the United States and Canada, 2000-2010. <i>Journal of Infectious Diseases</i> , 2016, 214, 862-872.	4.0	116
13	The Scope and Impact of Treatment of Latent Tuberculosis Infection in the United States and Canada. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 173, 927-931.	5.6	103
14	Contributions of traditional and HIV-related risk factors on non-AIDS-defining cancer, myocardial infarction, and end-stage liver and renal diseases in adults with HIV in the USA and Canada: a collaboration of cohort studies. <i>Lancet HIV</i> , 2019, 6, e93-e104.	4.7	94
15	RISK6, a 6-gene transcriptomic signature of TB disease risk, diagnosis and treatment response. <i>Scientific Reports</i> , 2020, 10, 8629.	3.3	90
16	Cause-Specific Mortality in HIV-Positive Patients Who Survived Ten Years after Starting Antiretroviral Therapy. <i>PLoS ONE</i> , 2016, 11, e0160460.	2.5	86
17	Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study. <i>Clinical Infectious Diseases</i> , 2015, 61, 527-535.	5.8	79
18	Risk and Timing of Tuberculosis Among Close Contacts of Persons with Infectious Tuberculosis. <i>Journal of Infectious Diseases</i> , 2018, 218, 1000-1008.	4.0	62

#	ARTICLE	IF	CITATIONS
19	Risk of Incident Diabetes Mellitus, Weight Gain, and Their Relationships With Integrase Inhibitor-Based Initial Antiretroviral Therapy Among Persons With Human Immunodeficiency Virus in the United States and Canada. <i>Clinical Infectious Diseases</i> , 2021, 73, e2234-e2242.	5.8	59
20	High Proportion of Heteroresistance in <i>gyrA</i> and <i>gyrB</i> in Fluoroquinolone-Resistant <i>Mycobacterium tuberculosis</i> Clinical Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3270-3275.	3.2	58
21	Prevalence, Risk Factors, and Treatment Outcomes of Isoniazid- and Rifampicin- Mono-Resistant Pulmonary Tuberculosis in Lima, Peru. <i>PLoS ONE</i> , 2016, 11, e0152933.	2.5	55
22	Mortality According to CD4 Count at Start of Combination Antiretroviral Therapy Among HIV-infected Patients Followed for up to 15 Years After Start of Treatment: Collaborative Cohort Study. <i>Clinical Infectious Diseases</i> , 2016, 62, 1571-1577.	5.8	52
23	Sex, Race, and HIV Risk Disparities in Discontinuity of HIV Care After Antiretroviral Therapy Initiation in the United States and Canada. <i>AIDS Patient Care and STDs</i> , 2017, 31, 129-144.	2.5	50
24	Geographic Variations in Retention in Care among HIV-Infected Adults in the United States. <i>PLoS ONE</i> , 2016, 11, e0146119.	2.5	47
25	The Relationship Between Latent Tuberculosis Infection and Acute Myocardial Infarction. <i>Clinical Infectious Diseases</i> , 2018, 66, 886-892.	5.8	46
26	Recent Abacavir Use Increases Risk of Type 1 and Type 2 Myocardial Infarctions Among Adults With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 78, 62-72.	2.1	43
27	Differential Expression of Activation Markers by <i>Mycobacterium tuberculosis</i> -specific CD4+ T Cell Distinguishes Extrapulmonary From Pulmonary Tuberculosis and Latent Infection. <i>Clinical Infectious Diseases</i> , 2020, 71, 1905-1911.	5.8	39
28	Increased non-AIDS mortality among persons with AIDS-defining events after antiretroviral therapy initiation. <i>Journal of the International AIDS Society</i> , 2018, 21, e25031.	3.0	38
29	RePORT International: Advancing Tuberculosis Biomarker Research Through Global Collaboration. <i>Clinical Infectious Diseases</i> , 2015, 61, S155-S159.	5.8	37
30	Systematic review of prediction models for pulmonary tuberculosis treatment outcomes in adults. <i>BMJ Open</i> , 2021, 11, e044687.	1.9	36
31	Transmission of <i>Mycobacterium tuberculosis</i> from Health Care Workers. <i>New England Journal of Medicine</i> , 2006, 355, 118-121.	27.0	35
32	Increased vitamin D receptor expression from macrophages after stimulation with <i>M. tuberculosis</i> among persons who have recovered from extrapulmonary tuberculosis. <i>BMC Infectious Diseases</i> , 2019, 19, 366.	2.9	35
33	Factors Associated With Noncompletion of Latent Tuberculosis Infection Treatment: Experience From the PREVENT TB Trial in the United States and Canada. <i>Clinical Infectious Diseases</i> , 2016, 62, 1390-1400.	5.8	34
34	Tuberculosis Meningitis. <i>Current Infectious Disease Reports</i> , 2017, 19, 39.	3.0	34
35	Risk Factors for Tuberculosis After Highly Active Antiretroviral Therapy Initiation in the United States and Canada: Implications for Tuberculosis Screening. <i>Journal of Infectious Diseases</i> , 2011, 204, 893-901.	4.0	33
36	Efavirenz Pharmacogenetics and Weight Gain Following Switch to Integrase Inhibitor-Containing Regimens. <i>Clinical Infectious Diseases</i> , 2021, 73, e2153-e2163.	5.8	32

#	ARTICLE	IF	CITATIONS
37	Guidelines for the treatment of latent tuberculosis infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020. <i>American Journal of Transplantation</i> , 2020, 20, 1196-1206.	4.7	31
38	Mortality Among Persons Entering HIV Care Compared With the General U.S. Population. <i>Annals of Internal Medicine</i> , 2021, 174, 1197-1206.	3.9	31
39	Treatment of Latent Tuberculosis Infection—An Update. <i>Clinics in Chest Medicine</i> , 2019, 40, 839-848.	2.1	30
40	Daily Marijuana Use is Associated with Missed Clinic Appointments Among HIV-Infected Persons Engaged in HIV Care. <i>AIDS and Behavior</i> , 2017, 21, 1996-2004.	2.7	28
41	The relationship between adverse neighborhood socioeconomic context and HIV continuum of care outcomes in a diverse HIV clinic cohort in the Southern United States. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2018, 30, 1426-1434.	1.2	27
42	HIV-1 Transmission Clustering and Phylodynamics Highlight the Important Role of Young Men Who Have Sex with Men. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 879-888.	1.1	27
43	Health Literacy and Demographic Disparities in HIV Care Continuum Outcomes. <i>AIDS and Behavior</i> , 2018, 22, 2604-2614.	2.7	26
44	Trends in Hepatocellular Carcinoma Incidence and Risk Among Persons With HIV in the US and Canada, 1996-2015. <i>JAMA Network Open</i> , 2021, 4, e2037512.	5.9	26
45	Risk of HCC With Hepatitis B Viremia Among HIV/HBV-Coinfected Persons in North America. <i>Hepatology</i> , 2021, 74, 1190-1202.	7.3	26
46	CD4/CD8 Ratio and Cancer Risk Among Adults With HIV. <i>Journal of the National Cancer Institute</i> , 2022, 114, 854-862.	6.3	26
47	Identification of Mycobacterium tuberculosis Peptides in Serum Extracellular Vesicles from Persons with Latent Tuberculosis Infection. <i>Journal of Clinical Microbiology</i> , 2020, 58, .	3.9	25
48	Novel stepwise approach to assess representativeness of a large multicenter observational cohort of tuberculosis patients: The example of RePORT Brazil. <i>International Journal of Infectious Diseases</i> , 2021, 103, 110-118.	3.3	25
49	Implementation of Tuberculosis Intensive Case Finding, Isoniazid Preventive Therapy, and Infection Control ("Three I's") and HIV-Tuberculosis Service Integration in Lower Income Countries. <i>PLoS ONE</i> , 2016, 11, e0153243.	2.5	24
50	Diagnosis and clinical outcomes of extrapulmonary tuberculosis in antiretroviral therapy programmes in low- and middle-income countries: a multicohort study. <i>Journal of the International AIDS Society</i> , 2019, 22, e25392.	3.0	24
51	Determinants of Restoration of CD4 and CD8 Cell Counts and Their Ratio in HIV-1-Positive Individuals With Sustained Virological Suppression on Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 80, 292-300.	2.1	24
52	Duration of Exposure Among Close Contacts of Patients With Infectious Tuberculosis and Risk of Latent Tuberculosis Infection. <i>Clinical Infectious Diseases</i> , 2020, 71, 1627-1634.	5.8	24
53	Risk Factors for Tuberculosis and Effect of Preventive Therapy Among Close Contacts of Persons With Infectious Tuberculosis. <i>Clinical Infectious Diseases</i> , 2020, 70, 1562-1572.	5.8	23
54	Tuberculosis in Antiretroviral Treatment Programs in Lower Income Countries: Availability and Use of Diagnostics and Screening. <i>PLoS ONE</i> , 2013, 8, e77697.	2.5	23

#	ARTICLE	IF	CITATIONS
55	Timing of Antiretroviral Therapy Initiation and Risk of Cancer Among Persons Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2021, 72, 1900-1909.	5.8	22
56	CD4/CD8 Ratio and CD4 Nadir Predict Mortality Following Noncommunicable Disease Diagnosis in Adults Living with HIV. <i>AIDS Research and Human Retroviruses</i> , 2019, 35, 960-967.	1.1	21
57	Latent Tuberculosis Infection and Subclinical Coronary Atherosclerosis in Peru and Uganda. <i>Clinical Infectious Diseases</i> , 2021, 73, e3384-e3390.	5.8	21
58	Pharmacokinetics and Drug-Drug Interactions of Isoniazid and Efavirenz in Pregnant Women Living With HIV in High TB Incidence Settings: Importance of Genotyping. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1034-1044.	4.7	20
59	HIV and cancer: a comparative retrospective study of Brazilian and U.S. clinical cohorts. <i>Infectious Agents and Cancer</i> , 2015, 10, 4.	2.6	18
60	Immune Function in Young Children With Previous Pulmonary or Miliary/Meningeal Tuberculosis and Impact of BCG Vaccination. <i>Pediatrics</i> , 2007, 120, e912-e921.	2.1	17
61	Diagnosis and treatment of latent tuberculosis infection: an update. <i>Current Respiratory Care Reports</i> , 2013, 2, 199-207.	0.6	17
62	Increased Mortality After Tuberculosis Treatment Completion in Persons Living With Human Immunodeficiency Virus in Latin America. <i>Clinical Infectious Diseases</i> , 2020, 71, 215-217.	5.8	15
63	Polymorphisms in TLR4 and TNFA and Risk of Mycobacterium tuberculosis Infection and Development of Active Disease in Contacts of Tuberculosis Cases in Brazil: A Prospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2019, 69, 1027-1035.	5.8	14
64	Determinants of Liver Complications Among HIV/Hepatitis B Virus-Coinfected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 82, 71-80.	2.1	14
65	Polymorphisms in interferon pathway genes and risk of Mycobacterium tuberculosis infection in contacts of tuberculosis cases in Brazil. <i>International Journal of Infectious Diseases</i> , 2020, 92, 21-28.	3.3	13
66	Accounting for dependent errors in predictors and time-to-event outcomes using electronic health records, validation samples and multiple imputation. <i>Annals of Applied Statistics</i> , 2020, 14, 1045-1061.	1.1	13
67	Latent tuberculosis infection is associated with increased unstimulated levels of interferon-gamma in Lima, Peru. <i>PLoS ONE</i> , 2018, 13, e0202191.	2.5	12
68	The Effect of Diabetes and Prediabetes on Mycobacterium tuberculosis Transmission to Close Contacts. <i>Journal of Infectious Diseases</i> , 2021, 224, 2064-2072.	4.0	12
69	A novel resistance mutation in eccC <sub>5</sub> of the ESX-5 secretion system confers ofloxacin resistance in Mycobacterium tuberculosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2419-2427.	3.0	11
70	Tuberculosis Burden and Determinants of Treatment Outcomes According to Age in Brazil: A Nationwide Study of 896,314 Cases Reported Between 2010 and 2019. <i>Frontiers in Medicine</i> , 2021, 8, 706689.	2.6	11
71	Mood Disorders and Increased Risk of Noncommunicable Disease in Adults With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 83, 397-404.	2.1	10
72	Five-Year Mortality for Adults Entering Human Immunodeficiency Virus Care Under Universal Early Treatment Compared With the General US Population. <i>Clinical Infectious Diseases</i> , 2022, 75, 867-874.	5.8	10

#	ARTICLE	IF	CITATIONS
73	One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. <i>New England Journal of Medicine</i> , 2019, 381, e23.	27.0	9
74	Effects of Pregnancy and Isoniazid Preventive Therapy on Mycobacterium tuberculosis Interferon Gamma Response Assays in Women With HIV. <i>Clinical Infectious Diseases</i> , 2020, 73, e3555-e3562.	5.8	9
75	OUP accepted manuscript. <i>Journal of Infectious Diseases</i> , 2021, , .	4.0	9
76	A Clinical Prediction Model for Unsuccessful Pulmonary Tuberculosis Treatment Outcomes. <i>Clinical Infectious Diseases</i> , 2022, 74, 973-982.	5.8	9
77	Determinants of losses in the latent tuberculosis infection cascade of care in Brazil. <i>BMJ Global Health</i> , 2021, 6, e005969.	4.7	9
78	25-Hydroxyvitamin D levels after recovery from tuberculosis: Insights into pathogenesis. <i>Tuberculosis</i> , 2014, 94, 51-54.	1.9	8
79	Health outcomes among HIV-positive Latinos initiating antiretroviral therapy in North America versus Central and South America. <i>Journal of the International AIDS Society</i> , 2016, 19, 20684.	3.0	8
80	LB9. The Effect of Initiating Integrase Inhibitor-based vs. Non-Nucleoside Reverse Transcriptase Inhibitor-based Antiretroviral Therapy on Progression to Diabetes among North American Persons in HIV Care. <i>Open Forum Infectious Diseases</i> , 2019, 6, S996-S997.	0.9	8
81	Self-reported Cannabis Use and Changes in Body Mass Index, CD4 T-Cell Counts, and HIV-1 RNA Suppression in Treated Persons with HIV. <i>AIDS and Behavior</i> , 2020, 24, 1275-1280.	2.7	8
82	Increased Neutrophil Count and Decreased Neutrophil CD15 Expression Correlate With TB Disease Severity and Treatment Response Irrespective of HIV Co-infection. <i>Frontiers in Immunology</i> , 2020, 11, 1872.	4.8	8
83	Knowledge and stigma of latent tuberculosis infection in Brazil: implications for tuberculosis prevention strategies. <i>BMC Public Health</i> , 2020, 20, 897.	2.9	8
84	Pre-Treatment Neutrophil Count as a Predictor of Antituberculosis Therapy Outcomes: A Multicenter Prospective Cohort Study. <i>Frontiers in Immunology</i> , 2021, 12, 661934.	4.8	8
85	CD4 Count at Entry into Care and at Antiretroviral Therapy Prescription among Adults with Human Immunodeficiency Virus in the United States, 2005-2018. <i>Clinical Infectious Diseases</i> , 2021, 73, e2334-e2337.	5.8	8
86	ODELAM, rapid sequence-independent detection of drug resistance in isolates of Mycobacterium tuberculosis. <i>ELife</i> , 2020, 9, .	6.0	8
87	Optimizing the Design of Latent Tuberculosis Treatment Trials: Insights from Mathematical Modeling. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 598-605.	5.6	7
88	Lack of Weight Gain During the First 2 Months of Treatment and Human Immunodeficiency Virus Independently Predict Unsuccessful Treatment Outcomes in Tuberculosis. <i>Journal of Infectious Diseases</i> , 2020, 221, 1416-1424.	4.0	6
89	Clinical Effectiveness of Integrase Strand Transfer Inhibitor-Based Antiretroviral Regimens Among Adults With Human Immunodeficiency Virus: A Collaboration of Cohort Studies in the United States and Canada. <i>Clinical Infectious Diseases</i> , 2020, 73, e1408-e1414.	5.8	6
90	Resistance-Confering Mutations on Whole-Genome Sequencing of Fluoroquinolone-resistant and -Susceptible Mycobacterium tuberculosis Isolates: A Proposed Threshold for Identifying Resistance. <i>Clinical Infectious Diseases</i> , 2021, 72, 1910-1918.	5.8	6

#	ARTICLE	IF	CITATIONS
91	Hepatitis C Coinfection and Mortality in People Living with HIV in Middle Tennessee. <i>AIDS Research and Human Retroviruses</i> , 2020, 36, 193-199.	1.1	5
92	Comparative Efficacy of Rifapentine Alone and in Combination with Isoniazid for Latent Tuberculosis Infection: a Translational Pharmacokinetic-Pharmacodynamic Modeling Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0170521.	3.2	5
93	Lessons Learned from Implementation of an Interferon Gamma Release Assay to Screen for Latent Tuberculosis Infection in a Large Multicenter Observational Cohort Study in Brazil. <i>Microbiology Spectrum</i> , 2021, 9, e0116321.	3.0	5
94	Virologic outcomes among adults with HIV using integrase inhibitor-based antiretroviral therapy. <i>Aids</i> , 2022, 36, 277-286.	2.2	5
95	Early Retention in Care Neither Mediates Nor Modifies the Effect of Sex and Sexual Mode of HIV Acquisition on HIV Survival in the Americas. <i>AIDS Patient Care and STDs</i> , 2018, 32, 306-313.	2.5	4
96	Treatment of latent M. tuberculosis infection and use of antiretroviral therapy to prevent tuberculosis. <i>Journal of Clinical Investigation</i> , 2020, 130, 5102-5104.	8.2	4
97	Increased Frequency of Memory CD4+ T-Cell Responses in Individuals With Previously Treated Extrapulmonary Tuberculosis. <i>Frontiers in Immunology</i> , 2020, 11, 605338.	4.8	4
98	Secular Trends in Breast Cancer Risk Among Women With HIV Initiating ART in North America. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 87, 663-670.	2.1	3
99	Do contemporary antiretrovirals increase the risk of end-stage liver disease? Signals from patients starting therapy in the North American AIDS Cohort Collaboration on Research and Design. <i>Pharmacoepidemiology and Drug Safety</i> , 2022, 31, 214-224.	1.9	3
100	Reversion of phenotypic fluoroquinolone resistance in <i>Mycobacterium tuberculosis</i> . <i>International Journal of Tuberculosis and Lung Disease</i> , 2016, 20, 1276-1277.	1.2	2
101	Trends and Disparities in Mortality and Progression to AIDS in the Highly Active Antiretroviral Therapy Era: Tennessee, 1996-2016. <i>American Journal of Public Health</i> , 2019, 109, 1266-1272.	2.7	2
102	Using a Composite Maternal-Infant Outcome Measure in Tuberculosis-Prevention Studies Among Pregnant Women. <i>Clinical Infectious Diseases</i> , 2020, 73, e587-e593.	5.8	2
103	Mortality Among People With HIV Treated for Tuberculosis Based on Positive, Negative, or No Bacteriologic Test Results for Tuberculosis: The IeDEA Consortium. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa006.	0.9	2
104	Fluoroquinolone susceptibility in first-line drug-susceptible M. tuberculosis isolates in Lima, Peru. <i>BMC Research Notes</i> , 2021, 14, 413.	1.4	2
105	Low Rates of Contraception Use in Women With Human Immunodeficiency Virus. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac113.	0.9	2
106	High mortality among patients hospitalized for drug-resistant tuberculosis with acquired second-line drug resistance and high HIV prevalence. <i>HIV Medicine</i> , 2022, 23, 1085-1097.	2.2	2
107	TB TREATMENT OUTCOMES IN BRAZIL: DIFFERENT PREDICTORS FOR EACH TYPE OF UNSUCCESSFUL OUTCOME. <i>Clinical Infectious Diseases</i> , 0, , .	5.8	2
108	Hormonal Contraception and Risk of Psychiatric and Other Noncommunicable Diseases in HIV-Infected Women. <i>Journal of Women's Health</i> , 2015, 24, 481-488.	3.3	1



#	ARTICLE	IF	CITATIONS
109	Weight Gain After Switch from Efavirenz-Based to Integrase Inhibitor-Based Regimens. Open Forum Infectious Diseases, 2017, 4, S433-S433.	0.9	1
110	Directly observed therapy and risk of unfavourable tuberculosis treatment outcomes among an international cohort of people living with HIV in low- and middle-income countries. Journal of the International AIDS Society, 2019, 22, e25423.	3.0	1
111	Re-evaluation of a novel resistance mutation in <i>eccC5</i> of the ESX-5 secretion system in ofloxacin-resistant <i>Mycobacterium tuberculosis</i> . Journal of Antimicrobial Chemotherapy, 2021, 76, 820-822.	3.0	1
112	Development and Validation of a Model for Prediction of End-Stage Liver Disease in People With HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2022, 89, 396-404.	2.1	1
113	Prevalence and Clinical Profiling of Dysglycemia and HIV Infection in Persons With Pulmonary Tuberculosis in Brazil. Frontiers in Medicine, 2021, 8, 804173.	2.6	1
114	The need for randomised controlled trials of isoniazid monoresistant tuberculosis treatment. Lancet Infectious Diseases, The, 2017, 17, 363-364.	9.1	0
115	1387. Women Living with HIV (WLWH) Lose IFN $\gamma$ Responses Diagnostic of Latent TB Infection (LTBI) during Pregnancy and after INH Prophylactic Treatment (IPT). Open Forum Infectious Diseases, 2019, 6, S504-S504.	0.9	0
116	4298 Prediction models for pulmonary tuberculosis treatment outcomes: a systematic review. Journal of Clinical and Translational Science, 2020, 4, 34-34.	0.6	0
117	Reply to Swindells et al.: Trials of Tuberculosis-Preventive Therapy in People with HIV Infection. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 305-306.	5.6	0
118	1648. CD4 T Lymphocyte and Monocyte Activation within One Year After Treatment Completion for Pulmonary Tuberculosis: A Pilot Study. Open Forum Infectious Diseases, 2020, 7, S812-S812.	0.9	0
119	53. Sex and Race Disparities in Premature Mortality among People with HIV: A 21-Year Observational Cohort Study. Open Forum Infectious Diseases, 2021, 8, S37-S37.	0.9	0